Compare DNOW & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNOW | MLYS |
|---|---|---|
| Founded | 1862 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 2014 | 2023 |
| Metric | DNOW | MLYS |
|---|---|---|
| Price | $11.26 | $27.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.67 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 3.6M | 988.0K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,648,000,000.00 | N/A |
| Revenue This Year | $70.53 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.68 | N/A |
| 52 Week Low | $11.10 | $10.44 |
| 52 Week High | $17.48 | $47.65 |
| Indicator | DNOW | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 30.85 | 41.11 |
| Support Level | N/A | $26.85 |
| Resistance Level | $15.93 | $30.05 |
| Average True Range (ATR) | 0.56 | 1.76 |
| MACD | -0.11 | 0.08 |
| Stochastic Oscillator | 8.46 | 29.78 |
Dnow Inc is a company engaged in world-wide supplying of energy and industrial products and packaged, engineered process and production equipment with a legacy of over one sixty years. It offers a broad set of supply chain solutions combined with a suite of digital solutions branded as DigitalNOW that provide customers world-class technology for digital commerce, data and information management. Its locations provide products and solutions to exploration and production companies, midstream transmission and storage companies, refineries, chemical companies, utilities, mining, municipal water, manufacturers, engineering and construction companies. The Company has three reportable segments being United States, Canada and International.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.